Hypothesis

Serial measurement of serum growth differentiation factor-15 (GDF-15), an integrated stress response marker reflecting mitochondrial dysfunction, combined with a non-invasive skeletal muscle mitochondrial complex IV activity index derived from near-infrared spectroscopy (NIRS) oxygen extraction kinetics during standardized isometric contraction, predicts subclinical cardiac involvement in inflammatory myopathies (dermatomyositis, polymyositis, anti-synthetase syndrome) 8–20 weeks before conventional cardiac biomarker (troponin I/T, NT-proBNP) elevation.

Rationale

Inflammatory myopathies carry underappreciated cardiac risk: subclinical myocarditis occurs in 30–75% of patients at autopsy, yet clinical detection relies on late markers (troponin elevation, echocardiographic dysfunction). GDF-15 rises in response to mitochondrial stress across multiple tissues, including cardiomyocytes, and is elevated in heart failure, myocarditis, and mitochondrial myopathies. Skeletal muscle mitochondrial dysfunction — measurable non-invasively via NIRS-derived oxygen extraction recovery kinetics — may serve as a sentinel for systemic mitochondrial impairment affecting the myocardium.

The key insight: inflammatory myopathies produce a systemic mitochondrial insult (via interferon-driven disruption of oxidative phosphorylation complexes, particularly complex IV/cytochrome c oxidase). Skeletal muscle is more accessible to non-invasive functional assessment than myocardium, and mitochondrial dysfunction in skeletal muscle may precede — or at minimum parallel — cardiac mitochondrial compromise. A composite biomarker combining the systemic stress signal (GDF-15 trajectory) with tissue-level functional assessment (NIRS complex IV proxy) could detect the transition from purely skeletal to cardiac-skeletal mitochondrial failure.

Testable Predictions

1. Primary: In a prospective cohort of 120+ inflammatory myopathy patients followed quarterly, composite GDF-15 slope (>15% increase per 90 days) plus NIRS oxygen extraction half-recovery time prolongation (>20% from baseline) predicts cardiac MRI evidence of myocardial edema or late gadolinium enhancement with AUC >0.82, sensitivity >80%, 8–20 weeks before troponin elevation.

2. Secondary: Anti-mitochondrial antibody subtypes (anti-signal recognition particle, anti-Mi-2, anti-MDA5) show differential GDF-15/NIRS trajectories reflecting distinct cardiac risk profiles, with anti-SRP conferring highest and fastest cardiac transition.

3. Mechanistic: Skeletal muscle biopsy specimens from patients with elevated composite scores show reduced complex IV staining (COX-negative fibers >5%) and increased mitochondrial DNA heteroplasmy levels correlating with subsequent cardiac involvement.

Limitations

• NIRS measurements are confounded by subcutaneous adipose tissue thickness, skin pigmentation, and peripheral perfusion status (common in SSc overlap)
• GDF-15 lacks organ specificity — elevated in renal impairment, malignancy, and aging
• Cardiac MRI as reference standard introduces verification bias (not all patients will undergo CMR)
• Small sample sizes typical of myositis cohorts may limit subgroup analyses by antibody type
• Standardization of isometric contraction protocols across centers requires validation

Clinical Significance

Early cardiac involvement detection in inflammatory myopathies remains a critical unmet need. Current guidelines recommend echocardiography, but sensitivity for subclinical myocarditis is poor. A non-invasive, repeatable composite biomarker using serum GDF-15 (routine immunoassay) and NIRS (portable, bedside-capable device) could enable risk-stratified cardiac surveillance, earlier immunosuppressive escalation for cardioprotection, and reduced sudden cardiac death in this vulnerable population.

LES AI • DeSci Rheumatology